The management of hypersexuality in men and women

Sexual Offences, Crime and Misconduct Research Unit (SOCAMRU),
Department of Psychology,
Nottingham Trent University

Professor Belinda Winder

Acknowledgements: R Lievesley, Jessica Faulkner
Learning objectives

1. To recognise the impact of hypersexuality on individuals’ (male and female) wellbeing

2. To explore whether anti-libidinals (i, Selective Serotonin Reuptake Inhibitors (SSRIs), ii, Anti-androgens and iii, combined) are effective in reducing sexual compulsivity, sexual preoccupation

3. To be aware of any differences between SSRIs and anti-androgens in terms of (i) who they are prescribed for, (ii) effectiveness, (iii) side effects using data from a prison sample of patients

4. To understand the experiences of individuals post-medication for hypersexuality
Activity: Defining Preoccupation
Activity
Sexual Preoccupation & Hypersexuality

“an abnormally intense interest in sex that dominates psychological functioning” (Mann, Hanson & Thornton, 2010 pg. 198)

Terms used include:

• Sexual addiction (Marshall, Marshall, Moulden & Serran, 2008),
• Hypersexual disorder (Krueger & Kaplan, 2002)
• Hypersexuality (Kaplan & Krueger, 2010).

• *Loss of control, use of sex to counteract dysphoric mood, continuation of behaviour despite adverse consequences*
Sexual preoccupation broken down:

• Part 1: Sexual preoccupation: ‘an abnormally intense interest in sex that dominates psychological functioning’

  potentially resulting in:

• Part 2: A high frequency / excessive sexual behaviours with an impersonal element (hypersexuality)

  potentially to relieve:

• Part 3: Sexual urges
Discussion point: how much sexual activity is too much?
Possible explanations: Sexual Preoccupation & Hypersexuality

Obsessive Compulsive Disorder (OCD) (Garcia & Thibaut, 2010),
Impulsivity and a lack of self-control (Gold & Heffner, 1998)
• A poor coping mechanism for depression and anxiety (Bancroft & Vukadinovic, 2004)

• Maladaptive personality traits (Hanson & Morton-Bourgon, 2005).
Abuse and trauma during childhood

• Kingston et al (2017) reported the findings of a study of 529 adult men who had been convicted of a sexual offence.

• Psychological abuse in childhood and adolescence, especially by a father, was found to be the most prominent predictor of subsequent hypersexual thoughts and behaviour.
Indicators

Behaviours
• Watching others inappropriately
• Discussing sex frequently / bringing it into a conversation
• Repetitive paraphilic behaviours e.g. exhibitionism / voyeurism
• Using the toilet frequently (especially when discussing sexual content)
• Frequent masturbation
• Use of pornography or sexual material
• Engage in / seek high levels of sexual behaviour
• Difficulty controlling sexual arousal

Thoughts
• Thinking about sex a lot
• Sexual dissatisfaction
• Intrusive sexual fantasies and urges
• Offence related or dangerous paraphilic thoughts and fantasies
• Sexual thoughts / fantasies about staff
• Sexualising non-sexual situations / others

Functions of Sexual Behaviour
• Self medication for negative moods
• A coping strategy
• A way of defining the self

Relationship history
• First intercourse at an early age
• High number of sexual partners
• Majority of sexual relations involve impersonal sex (“one night stands”)
• Repeated unfaithfulness

Other
• Difficulty concentrating
• Appears distracted
• Tiredness / not sleeping

*Paraphilias are ‘recurrent, intense sexually arousing fantasies, sexual urges, or behaviors generally involving
• Non human objects
• Suffering or humiliation of self or partner
• Children or other non-consenting person

For at least 6 months and causing clinical distress or impairs social, occupational or important function

SOCAMRU
Sexual Offences, Crime and Misconduct Research Unit
Prevalence in the community

• Kinsey et al. (1948) reported that 7.6% of the male sample (n=14,083) had a total sexual outlet (TSO) of 7 or more (this is considered high). This finding contradicts earlier work by Pearl (1925) who claimed high frequencies of TSO are extremely rare.

• Discrepancies in the literature between the terms mean prevalence rates differ; some reasonable estimates are:
  - 3.0% for men and 1.2% for women on scores of compulsive sexual behaviour (used interchangeably with hypersexuality and sexual addiction; Odlaug et al., 2013)
  - 3.1% of women who responded to an online survey were characterised as hypersexual (Klein, Rettenberger & Briken, 2014; Reid, Garos & Carpenter, 2011)
Impact on wellbeing

Detrimental outcomes associated with hypersexuality include:

- Substance abuse (Opitz, Tsytsarev, & Froh, 2009)
- Contraction of sexually transmitted infections (Yoon et al., 2016)
- Unwanted pregnancies (Kafka, 2010)
- Job loss / relationship breakdown (Paunović & Hallberg, 2014)
- Financial losses (Reid et al., 2012)
- Physical injury (Carnes, 1991)

- Our research has added to these: interpersonal problems, isolation (social and emotional), depression, anxiety.
Current management and treatment of hypersexuality

- Rule out medical causes
- Consider medication to manage sexual arousal – together with therapy / psych treatment

Treated with 2 categories of medication: hormonal and non-hormonal medications.

Hormonal drug therapy includes anti-androgens (for example, cyproterone acetate) and gonadotropin-releasing hormone (GnRH) analogues (for example, triptorelin).

Cyproterone acetate (Androcur) is licensed for the control of libido in severe hypersexuality or sexual deviation in adult men.

Triptorelin (Salvacyl) is licensed for the reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations.

Non-hormonal drug therapy includes antipsychotics (off-label use) and selective serotonin reuptake inhibitors (off-label use) (Khan et al. 2015). (From NICE, 2017)
Is medication to manage sexual arousal effective?
Is medication to manage sexual arousal effective?

YES
Effectiveness assessed in a prison setting

• Hypersexuality/SP is an *enduring psychological risk factor* or long term vulnerability for sexual offending (Thornton & Knight, 2015)

• Sexual preoccupation is a significant predictor for sexual, violent and general recidivism (Hanson & Morton-Bourgon, 2004; Hanson, Harris, Scott & Helmus, 2007)

• Results are typically higher in sexual offender populations, with findings suggesting 44% of incarcerated sexual offenders were considered as hypersexual compared to 18% of a matched community sample (Marshall & Marshall, 2006; Marshall, Marshall, Moulden, & Serran, 2008; Marshall, O’Brien, & Kingston, 2009).
Research Context

HMP Whatton, a treatment prison in the UK, holds approximately 840 adult males convicted of a sexual offence

42% have a sentence of more than four years
56% are serving an indeterminate sentence including life sentence

Medication
Prescription guidelines from Dr Grubin
- Fluoxetine, Paroxetine (SSRIs)
- Cyproterone acetate (CPA, anti androgen)
- Triptorelin (GnRH agonist)

- See Winder et al. (2014; 2017) for evaluation or email me:
  Belinda.winder@ntu.ac.uk
Evaluation

150 + adult men referred for medication; initial medication was:
- 58% SSRIs
- 13% Anti-androgens
- 5% SSRIs & Anti-androgens
  - 1% GnRH
- 5% still under assessment
- 18% No medication (declined / not suitable)

Demographics
- Mean IQ (assessed by WASI or, where available WAIS) = 83.77 (sd = 14.88; 63-114) (*skewed towards lower IQ*)
- Mean age 45.13 (sd = 14.77; 24-81) (*reflecting ‘norm’ popn*)
- Age at first conviction = 20.33 (sd = 8.08)
- Nationality: Majority British (*reflecting ‘norm’ popn*)
- History of abuse: Yes, typically - bullying, s/p abuse
Evidence base in prison – HMP Whatton

Figure 1: Mean Sexual Compulsivity Scores for participants taking medication to reduce sexual preoccupation: pre-medication (T0), three months post-medication (T3) and six months post-medication (T6).

Below the ‘typical’ levels for people convicted of a sexual offence.
Sexual Compulsivity

SC of main sex offender population at Whatton

Anti-libidinal group have significantly higher Sexual Compulsivity

Young sexually active students
Evidence base in prison

Figure 3: Amount of time currently spent thinking about sex for participants taking (i) SSRIs and (ii) A-As

Figure 4: Ability to distract from sexual thoughts for participants taking (i) SSRIs and (ii) A-As

Figure 5: Strength of sexual urges for participants taking (i) SSRIs and (ii) A-As
What else did we find?

- Levels of psychometrically assessed personality disorder changed post medication.
- Anxiety and depression (HADS) also significantly reduced.
- The facets most problematic were effortful control, self-reflexive functioning, frustration tolerance, emotional regulation and stable self-image.
- Both statistical and clinically significant change was observed in adaptive personality functioning six months post medication.
- The majority of participants had moved into the healthy range of personality functioning within six months of taking medication.
Service user reports: effects of medication

• Sexual preoccupation and associated sexual behaviour
  o Decreased frequency & intensity of sexual thoughts, fantasies and urges
  o Reduction in masturbatory frequency
  o Increased control of sexual thoughts & ability to distract
  o Physical effects

• Obsessive compulsive disorder and depressive symptoms
  o Reduction in symptoms
  o Increased ability to communicate with others and to socialise

• Impulse and emotional control
  o Increased ability to recognise inappropriate sexual thoughts
  o Altered nature of fantasies
  o Improved management of emotions.

• Side effects
  o Tiredness, drowsiness, nausea, constipation and headaches
Conclusions and final thoughts

• Hypersexuality has implications for physical, emotional and mental health (of self and others)
• Medication has demonstrated significant reductions (both SSRIs and hormonal treatments) pre and post – in samples of adult men
• SSRIs are off-label for hypersexuality currently
• Hormonal treatment (CPA) requires routine monitoring
• For some individuals, it is a precursor to sexual offending – so, if someone is seeking help for this, your next steps are crucial
• For individuals concerned they may offend, there are a few channels of support (see LINKS on next slide) – but this does not mean that they are currently offending.
• There is likely to be an increase in the number of people referring themselves over the next few years….
Links

• Safer Living Foundation http://saferlivingfoundation.org/
• Lucy Faithfull Foundation http://www.lucyfaithfull.org.uk/
• Stop It Now http://www.stopitnow.org.uk/
• Online help for people concerned about accessing images http://get-help.stopitnow.org.uk/
• Support groups such as Sex Addicts Anonymous http://saauk.info/en/
• NICE guidelines :
References


*SOCAMRU*

*Sexual Offences, Crime and Misconduct Research Unit*


Research & Clinical Team

Prof Belinda Winder belinda.winder@ntu.ac.uk (contact re evaluation)

Jessica Faulkner

Dr Christine Norman

Helen Elliott

Rebecca Lievesley

Dr Kerensa Hocken

Dr Adarsh Kaul adarsh.kaul@nottsbc.nhs.uk (contact re prescribing / medication)
Additional slides

From here on – to expand on any points raised and possible qs
Testosterone levels

• 12 participants on Androcur with pre and post tests
• Serum testosterone levels nmol/L

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD) nmol/L</th>
<th>Range nmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre treatment</td>
<td>13.47 (6.6)</td>
<td>5.3-23.2</td>
</tr>
<tr>
<td>Post treatment</td>
<td>5.10 (2.92)</td>
<td>1.1-11.2</td>
</tr>
</tbody>
</table>

• Androcur significantly reduces Testosterone levels $p=0.0002$
• Pre treatment levels slightly higher than norm
<table>
<thead>
<tr>
<th>Service user studies</th>
<th><strong>Key features</strong></th>
<th><strong>Key findings</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To explore the use of anti-libidinals to reduce sexual preoccupation and/or hypersexuality in convicted sexual offenders</td>
<td></td>
<td>• Reduced sexual preoccupation &amp; arousal</td>
</tr>
<tr>
<td><strong>Participants:</strong> 19 adult male sex offenders</td>
<td></td>
<td>• Improved impulse &amp; emotional control</td>
</tr>
<tr>
<td><strong>Medication:</strong> Anti-androgens, SSRIs or combined</td>
<td></td>
<td>• Some noncompliance</td>
</tr>
<tr>
<td><strong>Analysis:</strong> Thematic analysis</td>
<td></td>
<td>• No prior knowledge of medication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Concerns about effects &amp; long term use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Therapist study</th>
<th><strong>Key features</strong></th>
<th><strong>Key findings</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To explore the experiences of individuals involved in the referral of pharmacological treatment and those who work with sexual offenders receiving pharmacological treatment</td>
<td></td>
<td>• Offenders’ concerns &amp; insight</td>
</tr>
<tr>
<td><strong>Participants:</strong> 8 intervention staff</td>
<td></td>
<td>• Lack of feedback</td>
</tr>
<tr>
<td><strong>Analysis:</strong> Thematic analysis</td>
<td></td>
<td>• Lack of awareness about treatment &amp; lack of support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Concerns about throughcare</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Offender supervisor study</th>
<th><strong>Key features</strong></th>
<th><strong>Key findings</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To explore the perspectives and experiences of offender supervisors in relation to the pharmacological treatment</td>
<td></td>
<td>• Offenders’ reluctance to engage</td>
</tr>
<tr>
<td><strong>Participants:</strong> 6 offender supervisors</td>
<td></td>
<td>• Lack of feedback</td>
</tr>
<tr>
<td><strong>Analysis:</strong> Thematic analysis</td>
<td></td>
<td>• Lack of awareness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Excluded from treatment process</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Importance of throughcare</td>
</tr>
</tbody>
</table>
Prescribing guidance: Prescribing unlicensed medicines

67. The term ‘unlicensed medicine’ is used to describe medicines that are used outside the terms of their UK licence or which have no licence for use in the UK. Unlicensed medicines are commonly used in some areas of medicine such as in paediatrics, psychiatry and palliative care. They are also used, less frequently, in other areas of medicine.

68. You should usually prescribe licensed medicines in accordance with the terms of their licence. However, you may prescribe unlicensed medicines where, on the basis of an assessment of the individual patient, you conclude, for medical reasons, that it is necessary to do so to meet the specific needs of the patient.

69. Prescribing unlicensed medicines may be necessary where:

a. There is no suitably licensed medicine that will meet the patient’s need. Examples include (but are not limited to), for example, where:
   i. there is no licensed medicine applicable to the particular patient. For example, if the patient is a child and a medicine licensed only for adult patients would meet the needs of the child; or
   ii. a medicine licensed to treat a condition or symptom in children would nonetheless not meet the specific assessed needs of the particular child patient, but a medicine licensed for the same condition or symptom in adults would do so; or
   iii. the dosage specified for a licensed medicine would not meet the patient’s need; or
   iv. the patient needs a medicine in a formulation that is not specified in an applicable licence.

b. Or where a suitably licensed medicine that would meet the patient’s need is not available. This may arise where, for example, there is a temporary shortage in supply; or

c. The prescribing forms part of a properly approved research project.

70. When prescribing an unlicensed medicine you must:

a. be satisfied that there is sufficient evidence or experience of using the medicine to demonstrate its safety and efficacy

b. take responsibility for prescribing the medicine and for overseeing the patient’s care, monitoring, and any follow up treatment, or ensure that arrangements are made for another suitable doctor to do so

c. make a clear, accurate and legible record of all medicines prescribed and, where you are not following common practice, your reasons for prescribing an unlicensed medicine.
Prescribing guidance: Prescribing unlicensed medicines

Information for patients about the licence for their medicines.

71. You must give patients (or their parents or carers) sufficient information about the medicines you propose to prescribe to allow them to make an informed decision.

72. Some medicines are routinely used outside the terms of their licence, for example in treating children. In emergencies or where there is no realistic alternative treatment and such information is likely to cause distress, it may not be practical or necessary to draw attention to the licence. In other cases, where prescribing unlicensed medicines is supported by authoritative clinical guidance, it may be sufficient to describe in general terms why the medicine is not licensed for the proposed use or patient population. You must always answer questions from patients (or their parents or carers) about medicines fully and honestly.

73. If you intend to prescribe unlicensed medicines where that is not routine or if there are suitably licensed alternatives available, you should explain this to the patient, and your reasons for doing so.

74. You should be careful about using medical devices for purposes for which they were not intended.